|Day Low/High||4.86 / 5.11|
|52 Wk Low/High||3.42 / 6.31|
Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and...
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Arotech Corporation (ARTX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Arotech to Greenbriar Equity Group, L.
NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr.
NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Chardan Heathcare Acquisition...
MILWAUKEE, Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc.
Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.
Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc.
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the May 2020 expiration.
Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept.
We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
Progenics' Self-Proclaimed "Master[s] of Commercialization" Continue to Underperform Under the Troubling Status Quo and Neglect to Publicly State Metrics and Goals to Assess Future Performance
Recorded First Revenues for AZEDRA ®; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL TM ( 18F-DCFPyL); Topline Data Expected...
Board Accepts Resignations of Directors Peter J. Crowley and Michael D.
Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed for Inpatient Medicare Patients
In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.83, changing hands as low as $4.72 per share.
Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
The collaboration with VA Greater Los Angeles Healthcare System is nation's first to validate deep learning algorithms in medical imaging of veterans with prostate cancer
Final Voting Results Confirm that Approximately Two-Thirds of the Votes Cast Were Against the Re-Election of Peter Crowley and Michael Kishbauch
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.